BioSpace News Archive

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced the closing of its previously announced business combination with Brookline Capital Acquisition Corp., a special purpose acquisition company.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced the appointments of Cynthia Burks and Charisse Sparks, M.D., as independent directors to its Board, effective July 28, 2022.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company will release its financial results for the second quarter ended June 30, 2022 on Tuesday, August 9, 2022.

Cullinan Oncology, Inc. today announced that its Chief Financial Officer, Jeff Trigilio, will participate in the following investor conferences in August.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce new interim data from 2nd line NSCLC patients (Part B) in the Phase II TACTI-002 trial.

CymaBay Therapeutics, Inc. today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the 2022 Alzheimer’s Association International Conference (AAIC).

Gracell Biotechnologies Inc. today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO).

Differentiated Therapeutics, a biotech company focused on computationally predicting and optimizing targeted protein degraders, announced the completion of a $5 million Seed financing.